Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Building on its history of successful collaborations, the global business unit at Sanofi responsible for vaccines is seeking partners with a common drive for excellence and pursuit of innovation.
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Precision diagnostics and monitoring company Oncocyte is developing the most comprehensive and rapid tumor-microenvironment gene-expression test to assess immunotherapeutic responsiveness. Combined with the company’s other tests, it provides a complete solution for cancer immunotherapy management and monitoring.
OncXerna Therapeutics is pioneering the use of artificial intelligence (AI) in the development of drugs and biomarkers for cancer, targeting patients’ tumor microenvironment (TME) to develop a precision-medicine approach that might identify those who will benefit most from the treatments in its pipeline.
Biophysics company Peptone is developing Oppenheimer, a protein-modeling platform that can transform undruggable intrinsically disordered proteins (IDPs) into developable drug candidates.
Marengo Therapeutics’ breakthrough discovery in T cell receptor (TCR) activation blazes a new trail for safe treatment and long-term protection against cancer.
Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.
Priothera’s immunomodulator mocravimod is an adjunctive and maintenance therapy for acute myeloid leukemia and is poised to enter a pivotal trial. It is now also being developed to unleash the full power of CAR-T therapy.
California-based Alamar Biosciences is beating antibodies at their own game, boosting affinity by targeting multiple epitopes on the same antigen using its Attobody platform.
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapies that activate and amplify targeted T cells to fight cancer. The company is seeking development and commercialization partners for several of its preclinical and clinical programs.
A novel platform that incorporates the human extracellular matrix is helping to accelerate drug development for diseases including fibrosis and solid tumors.
MaveriX Oncology has developed the IMPACT-2X platform for the design of first-in-class small-molecule therapeutics—which are conditionally activated by highly expressed hydroxylases in cancer and the tumor immune microenvironment (TIME)—to treat multiple solid tumors.
A next-generation diagnostic test developed by Haystack Oncology detects the presence of micrometastatic disease in patients who have received surgery for early-stage cancer. By identifying residual disease—which Haystack achieves through accurately measuring circulating tumor DNA—physicians can help their patients receive the appropriate type and duration of treatment and in doing so improve patient outcomes.
Genomics company Genomenon is combining the power of artificial intelligence with the experience of expert curators to produce an accurate assessment of genetic variants that cause disease to expedite development of diagnostics and target identification.
Ichnos Sciences is building multispecific antibodies for hematologic malignancies and solid tumor indications using its ‘plug-and-play’ platform and has clinical-grade manufacturing capabilities ready to deploy.
IO Biotech is developing T-win, a therapeutic cancer-vaccine technology designed to recruit naturally occurring T cells to disrupt multiple immunosuppressive processes in the tumor microenvironment. The lead candidate is in advanced clinical development for melanoma with plans to expand to other solid tumor indications.
Nabla Bio combines innovative artificial intelligence with proprietary wet-lab biology to design, refine and optimize next-generation therapeutic antibodies.